肾络方结肠透析治疗慢性肾衰竭高磷血症临床研究

A study on treating chronic renal failure hyperphosphatemia by colon dialysis with the Shenluo prescription

目的:观察肾络方结肠透析治疗脾肾阳虚型慢性肾衰竭高磷血症的临床疗效。方法:本临床试验根据完全随机分组对照的原则,将60例脾肾阳虚型慢性肾衰竭高磷血症患者随机分为治疗组和对照组,对照组给予口服碳酸钙加基础治疗;治疗组在对照组的基础上给予肾络方结肠透析治疗,两组均给予治疗3周,测定两组治疗前后血磷(P^3+)、血钙(Ca^2+)、血清肌酐(Scr)、尿素氮(BUN)、肌酐清除率(Ccr)水平。结果:治疗组与对照组均能降低患者血磷水平,但治疗组在降低血磷方面较对照组有明显优势(P<0.05);治疗组与对照组对血钙的治疗无明显差异;治疗组与对照组均可降低患者Scr水平,治疗组降低Scr、BUN的疗效优于对照组(P<0.05)。结论:肾络方结肠透析能够在一定程度上降低脾肾阳虚型慢性肾衰竭患者血磷水平、改善钙磷代谢,能够有效降低慢性肾衰竭患者肌酐、尿素氮水平,提高内生肌酐清除率,在一定程度上延缓病情发展。

Objective:To observe efficacy of colon dialysis with the Shenluo prescription(肾络方)on chronic renal failure hyperphosphatemia.Methods:60 cases were divided into 2 groups,30 cases in each.The control group was given oral calcium carbonate plus basic treatment.The treatment group was given colon dialysis with the Shenluo prescription more,for 3 weeks.Results:The blood phosphorus level in the two groups were decreased,and that in the treatment group was better(P<0.05).There was no significant difference in blood calcium levels between the two groups.Scr levels in the two groups were decreased,and the Scr and BUN indicators in the treatment group were better than those in the control group(P<0.05).Conclusion:Colon dialysis with the Shenluo prescription on chronic renal failure hyperphosphatemia can reduce blood phosphorus levels,creatinine,urea nitrogen levels,improve calcium and phosphorus metabolism,increase endogenous creatinine clearance,and delay the development of the disease.